Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is set to participate in the 13th Alzheimer’s & Parkinson’s Drug Development ...

The 13th Alzheimer’s & Parkinson’s Drug Development Summit is the only industry-focused, end-to-end meeting that provides comprehensive coverage from early discovery to late-stage development focused ...

Parkinson’s disease (PD) affects nearly 2% of adults over 65, making it the second most common neurodegenerative disorder. It ...

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a significantly elevated risk of Parkinson's disease, a neurodegenerative condition ...

A new study has identified genetic variants in the ITSN1 gene that significantly increase the risk of developing Parkinson’s disease.

Scientists have identified a gene that can significantly increase the risk of Parkinson's disease. | Genetics And Genomics ...

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a ...

Scientists have identified a rare genetic mutation in ITSN1 that increases the risk of Parkinson’s disease by up to tenfold, ...

MedRhythms today announced that MR-005, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been listed as a Class ...